[vc_row][vc_column][vc_column_text css=”.vc_custom_1632539686556{padding-top: 100px !important;padding-right: 50px !important;padding-bottom: 100px !important;padding-left: 50px !important;background-image: url(https://atlantis2.elsbiz.website/wp-content/uploads/2021/09/Screen-Shot-2021-09-24-at-12.15.55-PM.png?id=76151) !important;}”]

Anti-aging models and in vitro assays

Anti-aging model is based on human dermal fibroblast. Identify active ingredients among hundreds on our innovative high-throughput assays. Validate or study mechanism of action with dedicated bioassays.

[/vc_column_text][vc_row_inner][vc_column_inner width=”2/3″][vc_column_text css=”.vc_custom_1632567553883{padding-top: 80px !important;padding-right: 30px !important;padding-bottom: 50px !important;padding-left: 30px !important;}”]

• In vitro model that recapitulates key features of dry AMD pathophysiology, with a screenable endpoint (Live/dead cells in 96wp).
• Full phenotypic, molecular and functional characteristics of in situ RPE.

[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/3″][vc_single_image image=”76207″][/vc_column_inner][/vc_row_inner][vc_column_text css=”.vc_custom_1632565853586{padding-top: 50px !important;padding-bottom: 50px !important;background-image: url(https://atlantis2.elsbiz.website/wp-content/uploads/2021/09/AtlantisBioscience_dryAMD_bg.jpg?id=76200) !important;background-position: center !important;background-repeat: no-repeat !important;background-size: cover !important;}”]

Use our iPSC-derived in vitro model assay
to improve the relevance of
your ophthalmology dry AMD R&D

[/vc_column_text][vc_row_inner][vc_column_inner width=”2/3″][vc_single_image image=”76202″ img_size=”full”][/vc_column_inner][vc_column_inner width=”1/3″][vc_single_image image=”76204″ img_size=”full”][/vc_column_inner][/vc_row_inner][vc_row_inner css=”.vc_custom_1632568111453{margin-top: 80px !important;}”][vc_column_inner width=”1/3″][vc_column_text css=”.vc_custom_1632568189607{padding-top: 50px !important;padding-bottom: 50px !important;}”]

Screenable endpoint

Live/Dead in 96 wells plate

[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/3″][vc_single_image image=”76212″ img_size=”full”][/vc_column_inner][vc_column_inner width=”1/3″][vc_single_image image=”76213″][/vc_column_inner][/vc_row_inner][vc_column_text css=”.vc_custom_1632568328511{margin-top: 80px !important;}”]

AMD facts

• Age-related Macular Degeneration (AMD) is an ophthalmologic disease causing irreversible partial vision loss or for the worst cases blindness.
• AMD is the first cause of vision loss after 50 years old, and prevalence is about 25 % for people older than 75. It is estimated that it will affect nearly 196 million people worldwide in 2020, including 69 million cases in Europe (Wong et al., 2014).
• There are two kinds of this pathology : atrophic and exudative AMD, also called respectively dry and wet AMD.
• There are treatments for the exudative form such as anti-VEGF antibodies (ranibizumab and bevacizumab). The atrophic form, which corresponds to more than 90% of cases, doesn’t have any satisfactory therapeutic option exists to prevent vision loss (Schmier et al., 2006).

[/vc_column_text][/vc_column][/vc_row][vc_row css=”.vc_custom_1632524441138{margin-top: 100px !important;}”][vc_column][vc_cta h2=”Please reach out to us for any enquiries and collaborative work at” h2_font_container=”font_size:23|color:%23000000″ h2_google_fonts=”font_family:Roboto%3A100%2C100italic%2C300%2C300italic%2Cregular%2Citalic%2C500%2C500italic%2C700%2C700italic%2C900%2C900italic|font_style:500%20bold%20regular%3A500%3Anormal” txt_align=”center” style=”custom” add_button=”right” btn_title=”EMAIL US” btn_style=”custom” btn_custom_background=”#004a80″ btn_custom_text=”#ffffff” btn_size=”lg” btn_align=”right” btn_i_icon_fontawesome=”far fa-envelope” use_custom_fonts_h2=”true” btn_button_block=”true” btn_add_icon=”true” custom_text=”#000000″ btn_link=”url:mailto%3A%20businessdev%40atlantisbioscience.com”][/vc_cta][/vc_column][vc_column][/vc_column][/vc_row][vc_section][/vc_section]